Palvella Therapeutics, Inc.
PVLAPalvella Therapeutics, Inc. in brief
Palvella Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Massachusetts, USA. It was founded in 2000. Its market value was $2.2 B on 29 October 2026, which makes it the 6,081st largest listed company in the world and the 1,582nd largest in the USA on this site. In the year to December 2025 it had sales of $29 M and a net loss of $37 M. It employs about 29 people and Wesley H. Kaupinen is its chief executive. Its shares trade under the symbol PVLA (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Palvella Therapeutics, Inc.
On December 13, 2024, we completed the previously announced business combination with Legacy Palvella in accordance with the terms of the Merger Agreement, pursuant to which, among other matters, Merger Sub merged with and into Legacy Palvella, with Legacy Palvella surviving as our wholly owned subsidiary (such business combination, the Merger). In connection with the completion of the Merger, we changed our name from “Pieris Pharmaceuticals, Inc.” to “Palvella Therapeutics, Inc.,” and our business became primarily the business conducted by Legacy Palvella. We are now a clinical-stage biopharmaceutical company focused on developing and, if approved, commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies.
Palvella Therapeutics, Inc. timeline
- 2000
- 🏁· approximateFounded
- 2013
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2014
- ✎Renamed Pieris Pharmaceuticals, Inc.Formerly Marika Inc..
- 2015
- 🔔Initial public offering as Pieris Pharmaceuticals, Inc.Final prospectus filed with the SEC on 30 June 2015; shares registered for exchange trading on 24 June 2015.
- 2019
- 💰Record revenue of $46 millionFY2019, the highest of the 6 years on record.
- 2024
- ✎Renamed Palvella Therapeutics, Inc.Formerly Pieris Pharmaceuticals, Inc..
Events of Palvella Therapeutics, Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,239 (Jan 2020) · #3,451 (Jan 2021) · #3,664 (Jan 2022) · #4,568 (Dec 2022) · #5,223 (Jul 2023) · #4,392 (Jan 2024) · #1,677 (Oct 2026) · #1,583 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- 73.6×
- Price / book
- 77.0×
- Free cash flow yield
- -0.6%
- Net margin
- -127.0%
- Operating margin
- -131.7%
- Return on equity
- -133.0%
- Liabilities / assets
- 53.0%
- Revenue growth
- +65.3%
- R&D / revenue
- 20.5%
- Revenue per employee
- $1.0 M
- Profit per employee
- $-1.3 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-39M | $-42M | — |
| Dec 2024 | — | — | $-14M | $-17M | — |
| Dec 2023 | $43M | +65.3% | $-12M | $19M | 43.7% |
| Dec 2022 | $26M | -17.6% | $-43M | $-33M | -128.5% |
| Dec 2021 | $31M | +7.2% | $-52M | $-46M | -145.6% |
| Dec 2020 | $29M | -36.6% | $-34M | $-37M | -127.0% |
| Dec 2019 | $46M | +59.0% | $-27M | $-25M | -55.0% |
| Dec 2018 | $29M | — | $-31M | $-27M | -91.9% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-25M | — | — | $-3.71 | — |
| Dec 2024 | $-11M | — | — | $-7.83 | — |
| Dec 2023 | $-14M | $0M | $-14M | $2.17 | — |
| Dec 2022 | $-60M | $1M | $-61M | — | — |
| Dec 2021 | $-8M | $1M | $-9M | $-0.71 | — |
| Dec 2020 | $-46M | $3M | $-49M | $-0.68 | — |
| Dec 2019 | $-52M | $2M | $-55M | $-0.56 | — |
| Dec 2018 | $-1M | $2M | $-3M | $-0.50 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-25M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 5, 202610-QQuarterly report · period to Sep 2026
- Nov 5, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Oct 28, 20268-KCurrent reportOther events
- Aug 4, 202610-QQuarterly report · period to Jun 2026
- Aug 4, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Jul 14, 20268-KCurrent reportOther events
- Jun 30, 20268-KCurrent reportDirectors or officers changed
- Jun 16, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
- May 20, 20268-KCurrent reportOther events
- May 15, 20268-KCurrent reportOther events
- May 13, 20268-KCurrent reportOther events
- May 7, 20268-KCurrent reportResults of operations · Regulation FD disclosure
Official filings of Palvella Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $29 M
- Operating income
- $-39 M
- Net income
- $-37 M
For year ending December-2025
Balance sheet
- Total assets
- $60 M
- Total liabilities
- $32 M
- Total equity
- $28 M
As of December-2025
Top 100 institutional investors in Palvella Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Jennison Associates LLC | 1,101,652 | +141,033 (+14.68%) | 7.54% | $152 M | Nov 16, 2026 |
| 2 | Montanova Capital, LLC | 1,044,898 | -90,508 (-7.97%) | 7.15% | $144 M | Nov 16, 2026 |
| 3 | BlackRock, Inc. | 989,691 | +71,334 (+7.77%) | 6.77% | $137 M | Nov 13, 2026 |
| 4 | Frazier Life Sciences Management, L.P. | 882,400 | 0 (0.00%) | 6.04% | $122 M | Nov 16, 2026 |
| 5 | First Light Asset Management, LLC | 734,086 | -37,815 (-4.90%) | 5.02% | $101 M | Nov 16, 2026 |
| 6 | State Street Corp | 624,879 | -28,293 (-4.33%) | 4.27% | $86 M | Nov 12, 2026 |
| 7 | BVF Inc/il | 607,149 | -65,640 (-9.76%) | 4.15% | $84 M | Nov 16, 2026 |
| 8 | Price T Rowe Associates Inc /MD/ | 591,995 | -46,873 (-7.34%) | 4.05% | $82 M | Nov 16, 2026 |
| 9 | Vanguard Capital Management LLC | 540,712 | +26,918 (+5.24%) | 3.70% | $75 M | Nov 13, 2026 |
| 10 | Westfield Capital Management Co LP | 396,045 | New | 2.71% | $55 M | Nov 12, 2026 |
| 11 | Federated Hermes, Inc. | 332,422 | -100,593 (-23.23%) | 2.27% | $46 M | Nov 12, 2026 |
| 12 | Marshall Wace, LLP | 329,799 | +326,947 (+11463.78%) | 2.26% | $45 M | Nov 13, 2026 |
| 13 | Invesco Ltd. | 312,729 | +279,077 (+829.30%) | 2.14% | $43 M | Nov 12, 2026 |
| 14 | Geode Capital Management, LLC | 311,596 | +35,432 (+12.83%) | 2.13% | $43 M | Nov 6, 2026 |
| 15 | Frontier Capital Management Co LLC | 276,272 | -202,561 (-42.30%) | 1.89% | $38 M | Nov 16, 2026 |
| 16 | Primecap Management Co/ca/ | 268,609 | +12,427 (+4.85%) | 1.84% | $37 M | Nov 12, 2026 |
| 17 | Alliancebernstein L.P. | 254,969 | +1,801 (+0.71%) | 1.74% | $35 M | Nov 16, 2026 |
| 18 | Woodline Partners LP | 250,517 | -67,000 (-21.10%) | 1.71% | $35 M | Nov 16, 2026 |
| 19 | Eventide Asset Management, LLC | 231,484 | 0 (0.00%) | 1.58% | $32 M | Nov 13, 2026 |
| 20 | Orbimed Advisors LLC | 229,860 | -62,500 (-21.38%) | 1.57% | $32 M | Nov 16, 2026 |
| 21 | Emerald Advisers, LLC | 229,404 | -82 (-0.04%) | 1.57% | $32 M | Nov 9, 2026 |
| 22 | Siren, L.L.C. | 207,485 | -50,000 (-19.42%) | 1.42% | $29 M | Nov 12, 2026 |
| 23 | MPM Bioimpact LLC | 197,633 | -6,394 (-3.13%) | 1.35% | $27 M | Nov 16, 2026 |
| 24 | William Blair Investment Management, LLC | 195,070 | New | 1.33% | $27 M | Nov 6, 2026 |
| 25 | Bellevue Group AG | 155,000 | 0 (0.00%) | 1.06% | $21 M | Nov 16, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Goldman Sachs Group Inc | 151,841 | -49,673 (-24.65%) | 1.04% | $21 M | Nov 16, 2026 |
| 27 | Morgan Stanley | 145,065 | -36,363 (-20.04%) | 0.99% | $20 M | Nov 13, 2026 |
| 28 | Emerald Mutual Fund Advisers Trust | 142,111 | +12,264 (+9.44%) | 0.97% | $20 M | Nov 9, 2026 |
| 29 | Vanguard Portfolio Management LLC | 135,246 | +6,284 (+4.87%) | 0.93% | $19 M | Nov 13, 2026 |
| 30 | FMR LLC | 126,767 | -88,074 (-40.99%) | 0.87% | $17 M | Nov 10, 2026 |
| 31 | UBS Group AG | 118,459 | +45,933 (+63.33%) | 0.81% | $16 M | Nov 10, 2026 |
| 32 | First Turn Management, LLC | 109,871 | -46,579 (-29.77%) | 0.75% | $15 M | Nov 16, 2026 |
| 33 | Charles Schwab Investment Management Inc | 108,609 | +76,026 (+233.33%) | 0.74% | $15 M | Nov 16, 2026 |
| 34 | Northern Trust Corp | 107,062 | +9,869 (+10.15%) | 0.73% | $15 M | Nov 16, 2026 |
| 35 | Lord, Abbett & Co. LLC | 87,087 | New | 0.60% | $12 M | Nov 13, 2026 |
| 36 | Vanguard Fiduciary Trust Co | 86,774 | +12,779 (+17.27%) | 0.59% | $12 M | Nov 13, 2026 |
| 37 | Clio Asset Management LLC | 86,012 | -331 (-0.38%) | 0.59% | $12 M | Oct 13, 2026 |
| 38 | NEXTBio Capital Management LP | 80,409 | -9,500 (-10.57%) | 0.55% | $11 M | Nov 13, 2026 |
| 39 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 70,033 | +2,564 (+3.80%) | 0.48% | $10 M | Nov 16, 2026 |
| 40 | AWM Investment Company, Inc. | 69,416 | 0 (0.00%) | 0.47% | $10 M | Nov 13, 2026 |
| 41 | Bank Of America Corp /de/ | 68,771 | +14,217 (+26.06%) | 0.47% | $9 M | Nov 16, 2026 |
| 42 | Neuberger Berman Group LLC | 65,679 | -17,428 (-20.97%) | 0.45% | $9 M | Nov 13, 2026 |
| 43 | Aberdeen Group plc | 63,347 | -56,891 (-47.32%) | 0.43% | $9 M | Nov 10, 2026 |
| 44 | Seven Grand Managers, LLC | 60,000 | 0 (0.00%) | 0.41% | $8 M | Nov 16, 2026 |
| 45 | Clearbridge Investments, LLC | 59,240 | -101 (-0.17%) | 0.41% | $8 M | Nov 12, 2026 |
| 46 | Nicholas Investment Partners, LP | 56,162 | +6,444 (+12.96%) | 0.38% | $8 M | Nov 16, 2026 |
| 47 | Nan Fung Trinity (HK) LTD | 52,630 | New | 0.36% | $7 M | Nov 6, 2026 |
| 48 | Royce & Associates LP | 50,509 | +10,000 (+24.69%) | 0.35% | $7 M | Nov 9, 2026 |
| 49 | HSBC Holdings PLC | 50,001 | 0 (0.00%) | 0.34% | $7 M | Nov 16, 2026 |
| 50 | Silvercrest Asset Management Group LLC | 48,790 | +8,925 (+22.39%) | 0.33% | $7 M | Nov 16, 2026 |
| 51 | Russell Investments Group, Ltd. | 47,892 | +25,547 (+114.33%) | 0.33% | $7 M | Nov 6, 2026 |
| 52 | Ensign Peak Advisors, Inc | 45,359 | -6,301 (-12.20%) | 0.31% | $6 M | Nov 12, 2026 |
| 53 | Lisanti Capital Growth, LLC | 41,990 | -985 (-2.29%) | 0.29% | $6 M | Nov 5, 2026 |
| 54 | Renaissance Technologies LLC | 37,270 | -16,000 (-30.04%) | 0.26% | $5 M | Nov 12, 2026 |
| 55 | WCM Investment Management, LLC | 36,406 | -3,734 (-9.30%) | 0.25% | $5 M | Nov 10, 2026 |
| 56 | Bank of New York Mellon Corp | 33,172 | +2,585 (+8.45%) | 0.23% | $5 M | Nov 5, 2026 |
| 57 | Mutual Of America Capital Management LLC | 31,074 | -244 (-0.78%) | 0.21% | $4 M | Oct 23, 2026 |
| 58 | Nuveen, LLC | 28,612 | +3,381 (+13.40%) | 0.20% | $4 M | Nov 10, 2026 |
| 59 | Quadrature Capital Ltd | 24,352 | New | 0.17% | $3 M | Nov 13, 2026 |
| 60 | Blue Owl Capital Holdings LP | 23,003 | -13,256 (-36.56%) | 0.16% | $3 M | Nov 13, 2026 |
| 61 | ACT Capital Partners, L.P. | 22,500 | — | 0.15% | $3 M | Nov 6, 2026 |
| 62 | TD Asset Management Inc | 22,146 | -600 (-2.64%) | 0.15% | $3 M | Nov 13, 2026 |
| 63 | Legato Capital Management LLC | 20,163 | -3,327 (-14.16%) | 0.14% | $3 M | Nov 10, 2026 |
| 64 | Avidity Partners Management LP | 20,000 | -50,000 (-71.43%) | 0.14% | $3 M | Nov 16, 2026 |
| 65 | Swiss National Bank | 19,400 | 0 (0.00%) | 0.13% | $3 M | Nov 12, 2026 |
| 66 | Fifth Third Bancorp | 19,211 | -16,374 (-46.01%) | 0.13% | $3 M | Nov 5, 2026 |
| 67 | Millennium Management LLC | 19,147 | -33,065 (-63.33%) | 0.13% | $3 M | Nov 16, 2026 |
| 68 | Alps Advisors Inc | 19,099 | +4,743 (+33.04%) | 0.13% | $3 M | Nov 3, 2026 |
| 69 | Informed Momentum Co LLC | 19,056 | +207 (+1.10%) | 0.13% | $3 M | Nov 16, 2026 |
| 70 | Wellington Management Group LLP | 18,848 | -16,746 (-47.05%) | 0.13% | $3 M | Nov 16, 2026 |
| 71 | Manufacturers Life Insurance Company, The | 18,075 | +2,530 (+16.28%) | 0.12% | $2 M | Nov 13, 2026 |
| 72 | F/m Investments LLC | 17,958 | +512 (+2.93%) | 0.12% | $2 M | Nov 13, 2026 |
| 73 | XTX Topco Ltd | 17,327 | +8,466 (+95.54%) | 0.12% | $2 M | Nov 16, 2026 |
| 74 | SEI Investments Co | 16,012 | +3,205 (+25.03%) | 0.11% | $2 M | Nov 10, 2026 |
| 75 | Rafferty Asset Management, LLC | 15,725 | +4,364 (+38.41%) | 0.11% | $2 M | Nov 13, 2026 |
| 76 | Rhumbline Advisers | 15,525 | +1,997 (+14.76%) | 0.11% | $2 M | Nov 10, 2026 |
| 77 | iA Global Asset Management Inc. | 15,224 | New | 0.10% | $2 M | Oct 29, 2026 |
| 78 | Atle Fund Management AB | 14,924 | New | 0.10% | $2 M | Nov 12, 2026 |
| 79 | Calamos Advisors LLC | 13,361 | +2,882 (+27.50%) | 0.09% | $2 M | Nov 2, 2026 |
| 80 | Jpmorgan Chase & Co | 12,551 | +4,131 (+49.06%) | 0.09% | $2 M | Nov 12, 2026 |
| 81 | California State Teachers Retirement System | 12,525 | +1,363 (+12.21%) | 0.09% | $2 M | Nov 13, 2026 |
| 82 | Oak Ridge Investments LLC | 12,454 | +416 (+3.46%) | 0.09% | $2 M | Oct 30, 2026 |
| 83 | Deutsche Bank AG\ | 11,662 | -176 (-1.49%) | 0.08% | $2 M | Nov 6, 2026 |
| 84 | Cresset Asset Management, LLC | 11,629 | 0 (0.00%) | 0.08% | $2 M | Nov 16, 2026 |
| 85 | HRT Financial LP | 11,349 | New | 0.08% | $2 M | Nov 13, 2026 |
| 86 | Mariner, LLC | 10,612 | +251 (+2.42%) | 0.07% | $1 M | Nov 12, 2026 |
| 87 | Mitsubishi UFJ Asset Management (UK) Ltd. | 10,500 | +5,000 (+90.91%) | 0.07% | $1 M | Oct 22, 2026 |
| 88 | Knights of Columbus Asset Advisors LLC | 10,078 | +47 (+0.47%) | 0.07% | $1 M | Nov 5, 2026 |
| 89 | State Of Wisconsin Investment Board | 9,920 | +3,528 (+55.19%) | 0.07% | $1 M | Nov 16, 2026 |
| 90 | Blackstone Inc. | 9,122 | New | 0.06% | $1 M | Nov 16, 2026 |
| 91 | Citigroup Inc | 8,745 | -6,748 (-43.56%) | 0.06% | $1 M | Nov 4, 2026 |
| 92 | Martingale Asset Management L P | 8,706 | +300 (+3.57%) | 0.06% | $1 M | Nov 12, 2026 |
| 93 | Legal & General Group Plc | 8,061 | +67 (+0.84%) | 0.06% | $1 M | Nov 16, 2026 |
| 94 | VANGUARD ASSET MANAGEMENT, Ltd | 7,837 | +1,438 (+22.47%) | 0.05% | $1 M | Nov 13, 2026 |
| 95 | Exome Asset Management LLC | 7,809 | New | 0.05% | $1 M | Nov 16, 2026 |
| 96 | Vanguard Global Advisers, LLC | 7,256 | +1,047 (+16.86%) | 0.05% | $1 M | Nov 13, 2026 |
| 97 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 6,914 | +542 (+8.51%) | 0.05% | $1 M | Nov 16, 2026 |
| 98 | Creative Planning | 6,913 | +2,786 (+67.51%) | 0.05% | $1 M | Nov 2, 2026 |
| 99 | Wells Fargo & Company/mn | 6,621 | -6,387 (-49.10%) | 0.05% | $1 M | Nov 16, 2026 |
| 100 | MetLife Investment Management, LLC | 6,576 | +171 (+2.67%) | 0.04% | $1 M | Nov 16, 2026 |
Mutual funds holding Palvella Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 State Street SPDR S&P Biotech ETFSSGA Funds Management, Inc. | 408,678 | $62 M | 2.8% | 0.58% | +49% | Jun 30, 2026 |
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 388,390 | $59 M | 2.7% | <0.01% | +7.4% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 281,586 | $43 M | 1.9% | 0.05% | +49% | Jun 30, 2026 |
| 🇺🇸 Federated Hermes Kaufmann FundFederated Advisory Services Company | 276,556 | $38 M | 1.9% | 0.78% | no change | Jul 31, 2026 |
| 🇺🇸 Eventide Healthcare & Life Sciences FundEventide Asset Management, LLC | 231,484 | $35 M | 1.6% | 2.0% | no change | Jun 30, 2026 |
| 🇺🇸 PGIM Jennison Small Company FundPrudential Jennison Small Co Fund, Inc. | 202,900 | $31 M | 1.4% | 0.89% | +281% | Jun 30, 2026 |
| 🇺🇸 PRIMECAP Odyssey Aggressive Growth FundPRIMECAP Management Company | 209,825 | $29 M | 1.4% | 0.39% | +19% | Jul 31, 2026 |
| 🇺🇸 T. Rowe Price New Horizons Fund, Inc.T. Rowe Price Associates, Inc. | 164,144 | $25 M | 1.1% | 0.17% | +100% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Health Sciences Fund, Inc.T. Rowe Price Associates, Inc. | 144,220 | $22 M | 0.99% | 0.18% | −5.8% | Jun 30, 2026 |
| 🇺🇸 PGIM Jennison Health Sciences FundPGIM INVESTMENTS LLC | 183,037 | $22 M | 1.3% | 1.6% | no change | May 29, 2026 |
| 🇺🇸 Federated Hermes Kaufmann Small Cap FundFederated Advisory Services Company | 150,500 | $21 M | 1.0% | 0.73% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Growth FundFidelity Management & Research Company LLC | 143,740 | $20 M | 0.98% | 0.23% | +11% | Jul 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 113,586 | $17 M | 0.78% | 0.02% | +9.8% | Jun 30, 2026 |
| 🇺🇸 AB Small Cap Growth PortfolioAllianceBernstein L.P. | 109,498 | $17 M | 0.75% | 0.53% | −1.2% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 120,068 | $17 M | 0.82% | 0.05% | +56% | Jul 31, 2026 |
| 🇺🇸 T. Rowe Price Integrated U.S. Small-Cap Growth Equity FundT. Rowe Price Associates, Inc. | 105,729 | $16 M | 0.72% | 0.16% | +126% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 101,267 | $15 M | 0.69% | 0.10% | +71% | Jun 30, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 92,731 | $13 M | 0.63% | 0.52% | +29% | Jul 31, 2026 |
| 🇺🇸 abrdn Healthcare Investorsabrdn Inc. | 79,433 | $12 M | 0.54% | 0.89% | +45% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth K6 FundFidelity Management & Research Company LLC | 74,980 | $10 M | 0.51% | 0.23% | +14% | Jul 31, 2026 |
| 🇺🇸 ClearBridge Small Cap FundFRANKLIN TEMPLETON FUND ADVISER, LLC | 56,480 | $8 M | 0.39% | 1.1% | no change | Jul 31, 2026 |
| 🇺🇸 Emerald Growth FundRBB Fund, Inc. | 52,070 | $7 M | 0.36% | 0.49% | — | Jul 31, 2026 |
| 🇺🇸 Emerald Growth FundEmerald Mutual Fund Advisers Trust | 52,070 | $7 M | 0.36% | 0.47% | — | Apr 30, 2026 |
| 🇺🇸 abrdn Life Sciences Investorsabrdn Inc. | 40,805 | $6 M | 0.28% | 0.90% | +55% | Jun 30, 2026 |
| 🇺🇸 BlackRock Health Sciences Opportunities PortfolioBlackRock Advisors, LLC | 50,716 | $6 M | 0.35% | 0.10% | new | May 29, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 47,929 | $6 M | 0.33% | 0.01% | +19% | May 31, 2026 |
| 🇺🇸 Calamos Timpani Small Cap Growth FundCalamos Advisors LLC | 39,054 | $5 M | 0.27% | 0.71% | +22% | Jul 31, 2026 |
| 🇺🇸 Vanguard Explorer FundThe Vanguard Group, Inc. | 36,632 | $5 M | 0.25% | 0.02% | new | Jul 31, 2026 |
| 🇺🇸 Neuberger Small Cap Growth FundNeuberger Berman Investment Advisers LLC | 41,226 | $5 M | 0.28% | 0.70% | +58% | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 39,845 | $5 M | 0.27% | 0.03% | +11% | May 31, 2026 |
| 🇺🇸 Royce Smaller-Companies Growth FundRoyce & Associates, LP | 28,500 | $4 M | 0.19% | 1.8% | +46% | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 26,644 | $4 M | 0.18% | 0.05% | +56% | Jul 31, 2026 |
| 🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc. | 29,359 | $3 M | 0.20% | 0.02% | +27% | May 31, 2026 |
| 🇺🇸 Small Cap Core PortfolioAllianceBernstein L.P. | 21,576 | $3 M | 0.15% | 0.38% | no change | Jun 30, 2026 |
| 🇺🇸 BlackRock Health Sciences Term TrustBlackRock Advisors, LLC | 21,246 | $3 M | 0.15% | 0.30% | no change | Jun 30, 2026 |
| 🇺🇸 JNL Multi-Manager Small Cap Growth FundJackson National Asset Management, LLC | 20,998 | $3 M | 0.14% | 0.13% | +1.2% | Jun 30, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 20,508 | $3 M | 0.14% | 0.05% | +73% | Jun 30, 2026 |
| 🇺🇸 Invesco Health Care FundInvesco Advisers, Inc. | 20,783 | $3 M | 0.14% | 0.24% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard U.S. Momentum Factor ETFThe Vanguard Group, Inc. | 22,955 | $3 M | 0.16% | 0.15% | +20% | May 31, 2026 |
| 🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors | 14,654 | $2 M | 0.10% | <0.01% | +32% | Jun 30, 2026 |
| 🇺🇸 Moa Small Cap Value FundMUTUAL OF AMERICA CAPITAL MANAGEMENT LLC | 13,820 | $2 M | 0.09% | 0.51% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 17,334 | $2 M | 0.12% | <0.01% | +18% | May 31, 2026 |
| 🇺🇸 F/m Emerald Life Sciences Innovation ETFRBB Fund, Inc. | 17,254 | $2 M | 0.12% | 1.9% | — | May 31, 2026 |
| 🇺🇸 Select Biotechnology PortfolioFidelity Management & Research Company LLC | 16,700 | $2 M | 0.11% | 0.04% | no change | May 31, 2026 |
| 🇺🇸 Direxion Daily S&P Biotech Bull 3X SharesRAFFERTY ASSET MANAGEMENT, LLC | 13,887 | $2 M | 0.09% | 0.39% | −12% | Jul 31, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 13,674 | $2 M | 0.09% | 0.05% | +47% | Jul 31, 2026 |
| 🇺🇸 Invesco Dorsey Wright SmallCap Momentum ETFInvesco Capital Management LLC | 15,529 | $2 M | 0.11% | 0.44% | −9.9% | May 31, 2026 |
| 🇺🇸 Royce Small-Cap Trust, Inc.Royce & Associates, LP | 12,000 | $2 M | 0.08% | 0.07% | no change | Jun 30, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 11,937 | $2 M | 0.08% | 0.05% | +47% | Jun 30, 2026 |
| 🇺🇸 T.Rowe Price Small Cap Growth PortfolioBrighthouse Investment Advisers, LLC | 11,869 | $2 M | 0.08% | 0.16% | +95% | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 14,105 | $2 M | 0.10% | <0.01% | +20% | May 31, 2026 |
| 🇺🇸 ALPS Medical Breakthroughs ETFALPS Advisors, Inc. | 14,096 | $2 M | 0.10% | 1.0% | +34% | May 31, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 10,279 | $2 M | 0.07% | 0.10% | +87% | Jun 30, 2026 |
| 🇺🇸 PGIM Jennison Blend FundPGIM INVESTMENTS LLC | 12,791 | $2 M | 0.09% | 0.13% | new | May 29, 2026 |
| 🇺🇸 T. Rowe Price Health Sciences PortfolioT. Rowe Price Associates, Inc. | 9,807 | $1 M | 0.07% | 0.20% | +4.0% | Jun 30, 2026 |
| 🇺🇸 Carillon Chartwell Small Cap FundCarillon Tower Advisers, Inc. | 9,733 | $1 M | 0.07% | 0.59% | +4.5% | Jun 30, 2026 |
| 🇺🇸 M Capital Appreciation FundNorthern Lights Fund Trust II | 9,387 | $1 M | 0.06% | 0.45% | — | Jun 30, 2026 |
| 🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC | 10,185 | $1 M | 0.07% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Victory Small Cap Stock FundVictory Capital Management Inc. | 9,944 | $1 M | 0.07% | 0.14% | no change | Jul 31, 2026 |
| 🇺🇸 Calamos Growth FundCalamos Advisors LLC | 9,197 | $1 M | 0.06% | 0.07% | +9.9% | Jul 31, 2026 |
| 🇺🇸 Knights of Columbus Small Cap Equity FundKnights of Columbus Asset Advisors LLC | 9,159 | $1 M | 0.06% | 0.60% | +32% | Jul 31, 2026 |
| 🇺🇸 T. Rowe Price Integrated U.S. Small-Mid Cap Core Equity FundT. Rowe Price Associates, Inc. | 8,208 | $1 M | 0.06% | 0.06% | +135% | Jun 30, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 7,890 | $1 M | 0.05% | 0.03% | +49% | Jun 30, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 7,800 | $1 M | 0.05% | 0.05% | +59% | Jun 30, 2026 |
| 🇺🇸 M Capital Appreciation FundM Financial Investment Advisers, Inc. | 9,479 | $1 M | 0.06% | 0.45% | — | Mar 31, 2026 |
| 🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC | 8,482 | $1 M | 0.06% | 0.12% | +176% | Jul 31, 2026 |
| 🇺🇸 Transamerica T. Rowe Price Small Cap VPTransamerica Asset Management, Inc. | 7,634 | $1 M | 0.05% | 0.16% | +108% | Jun 30, 2026 |
| 🇺🇸 Nicholas Partners Small Cap Growth FundNicholas Investment Partners, L.P. | 7,426 | $1 M | 0.05% | 0.59% | +39% | Jun 30, 2026 |
| 🇺🇸 Carillon Chartwell Small Cap Growth FundCarillon Tower Advisers, Inc. | 7,147 | $1 M | 0.05% | 0.56% | +24% | Jun 30, 2026 |
| 🇺🇸 Small Company Growth PortfolioThe Vanguard Group, Inc. | 6,555 | $1 M | 0.04% | 0.06% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 6,500 | $1 M | 0.04% | 0.05% | +65% | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 6,227 | $1 M | 0.04% | <0.01% | −3.6% | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 7,742 | $1 M | 0.05% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Federated Hermes Kaufmann Fund IIFederated Advisory Services Company | 5,959 | $1 M | 0.04% | 0.81% | — | Jun 30, 2026 |
| 🇺🇸 Alger Small Cap Growth PortfolioFred Alger Management, LLC | 5,769 | $1 M | 0.04% | 0.54% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 5,621 | $1 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 5,550 | $1 M | 0.04% | 0.05% | +59% | Jun 30, 2026 |
| 🇺🇸 AVIP AB Small Cap PortfolioCONSTELLATION INVESTMENTS INC | 5,531 | $1 M | 0.04% | 0.27% | −8.6% | Jun 30, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 5,926 | $1 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 6,763 | $1 M | 0.05% | 0.05% | +9.1% | May 31, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 5,426 | $1 M | 0.04% | <0.01% | +14% | Jul 31, 2026 |
| 🇺🇸 LVIP Franklin Templeton Multi-Factor SMID Cap Equity FundLincoln Financial Investments Corporation | 4,831 | $1 M | 0.03% | 0.07% | +4.0% | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 5,240 | $1 M | 0.04% | 0.05% | +57% | Jul 31, 2026 |
| 🇺🇸 BlackRock Health Sciences TrustBlackRock Advisors, LLC | 4,480 | $1 M | 0.03% | 0.12% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity MSCI Health Care Index ETFFidelity Management & Research Company LLC | 4,864 | $1 M | 0.03% | 0.02% | +8.2% | Jul 31, 2026 |
| 🇺🇸 Biotechnology Ultrasector ProfundProFund Advisors LLC | 4,860 | $1 M | 0.03% | 0.34% | — | Apr 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 3,940 | $1 M | 0.03% | 0.03% | +57% | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 3,631 | $1 M | 0.02% | 0.05% | +41% | Jun 30, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 3,600 | $1 M | 0.02% | 0.02% | +33% | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 3,451 | $1 M | 0.02% | 0.05% | +52% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors | 3,332 | $1 M | 0.02% | <0.01% | +71% | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 3,654 | $1 M | 0.02% | 0.02% | +12% | Jul 31, 2026 |
| 🇺🇸 PACE Small/Medium Co Growth Equity InvestmentsUBS Asset Management (Americas) LLC | 3,499 | $0 M | 0.02% | 0.19% | +14% | Jul 31, 2026 |
| 🇺🇸 Health Sciences TrustJohn Hancock Variable Trust Advisers LLC | 3,173 | $0 M | 0.02% | 0.19% | −5.9% | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 3,154 | $0 M | 0.02% | 0.05% | +55% | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGoldman Sachs Asset Management, L.P. | 4,017 | $0 M | 0.03% | 0.05% | +1.4% | May 31, 2026 |
| 🇺🇸 BlackRock Advantage Small Cap Growth FundBlackRock Funds | 3,096 | $0 M | 0.02% | 0.06% | new | Jun 30, 2026 |
| 🇺🇸 Health Sciences PortfolioPacific Life Fund Advisors LLC | 3,008 | $0 M | 0.02% | 0.12% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index ETFFidelity Management & Research Company LLC | 3,843 | $0 M | 0.03% | <0.01% | −14% | May 31, 2026 |
| 🇺🇸 Voya MI Dynamic SMID Cap FundVoya Investments, LLC | 3,599 | $0 M | 0.02% | 0.30% | new | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Palvella Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Jeffrey S. MartiniChief Scientific Officer | Option exercise10b5-1 plan | +6,250 | $9.790 | $61 K | 6,250 | Form 4 |
| filed | Jeffrey S. MartiniChief Scientific Officer | Sell10b5-1 plan | -1,650 | $164.14 | $271 K | 4,600 | Form 4 |
| filed | Jeffrey S. MartiniChief Scientific Officer | Sell10b5-1 plan | -1,467 | $165.78 | $243 K | 3,133 | Form 4 |
| filed | Jeffrey S. MartiniChief Scientific Officer | Sell10b5-1 plan | -1,133 | $166.76 | $189 K | 2,000 | Form 4 |
| filed | Jeffrey S. MartiniChief Scientific Officer | Sell10b5-1 plan | -1,200 | $167.75 | $201 K | 800 | Form 4 |
| filed | Jeffrey S. MartiniChief Scientific Officer | Sell10b5-1 plan | -600 | $168.73 | $101 K | 200 | Form 4 |
| filed | Jeffrey S. MartiniChief Scientific Officer | Sell10b5-1 plan | -200 | $169.78 | $34 K | 0 | Form 4 |
| filed | Jeffrey S. MartiniChief Scientific Officer | Option exercise10b5-1 plan | +4,266 | $7.530 | $32 K | 4,266 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Palvella Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 2.273-for-1 split
Fails to deliver
- : 1,164 shares at $147.47
- : 24,390 shares at $132.91
- : 4,080 shares at $122.58
- : 3 shares at $128.00
- : 862 shares at $158.13
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Palvella Therapeutics, Inc. scorecard#
Passes 1 of the 13 checks that could be worked out. Fiscal year 2025; market cap of Oct 29, 2026.
Valuation0 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median77.0×Price to book 77.0× against Biotechnology's median of 2.9×.
- ✗Price to sales below its peers' median73.6×Price to sales 73.6× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-0.6%Free cash flow is -0.6% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-3.71 vs -7.83Diluted EPS -3.71 in fiscal 2025 against -7.83 the year before (report's currency).
- ✗Net income higher than five years earlier-$42 M-$42 M in fiscal 2025 against -$37 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$42 MNet income -$42 M in fiscal 2025.
- ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-92.1%-92.1% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities5.2×Current ratio 5.20 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year405.4%Diluted shares up 405.4% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Palvella Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | — | — | 43+65.3%100% | 26−17.6%100% | 31+7.1%100% | 29−36.6%100% | 46+59.0%100% | 29+15.1%100% | 25+333%100% | 5.8r5.8—100% | |
| Research and development | 23+180%— | 8.2−7.3%— | 8.8r42−83.4%20.5% | 53−20.5%205% | 67+43.3%212% | 47−15.4%159% | 55+32.6%119% | 41+86.2%143% | 22+13.1%88.2% | 20r20—338% | |
| General and administrative | 16+165%— | 5.9+93.2%— | 3.1r17−81.2%7.2% | 16−1.2%63.3% | 17−0.7%52.8% | 17−9.4%57.0% | 18−0.0%39.8% | 18+4.9%63.4% | 18+97.8%69.6% | 8.9r8.9—152% | |
| Operating expenses | 39+174%— | 14+18.8%— | 12r73−82.9%27.7% | 69−16.7%268% | 83+31.6%265% | 63−13.9%216% | 73+22.5%159% | 60+50.3%206% | 40+39.5%158% | 29r29—490% | |
| Operating income | −39—— | −14—— | −12r−30—−27.7% | −43—−168% | −52—−165% | −34—−116% | −27—−58.7% | −31—−106% | −15—−57.7% | −23r−23—−390% | |
| Interest expense and finance costs | 0−100%— | 0.4—— | 0—0.0% | — | — | — | — | — | — | — | |
| Net interest income | 2.6+303%— | 0.6—— | — | — | — | — | — | — | — | — | |
| Other non-operating income (expense) | 0.7—— | −0.1r0.5−118%— | 0.7r−0.3−45.4%1.7% | 1.3−45.8%5.0% | 2.4—7.7% | −3.7—−12.5% | −0.0−101%−0.1% | 1.8—6.2% | −2.1−1852%−8.3% | 0.1r0.1—2.1% | |
| Income before tax | −42—— | −17−193%— | 19r−25—43.7% | −33—−128% | −46—−146% | −37—−126% | −25—−55.0% | −27—−93.0% | −17—−65.5% | −23r−23—−388% | |
| Income tax | 0—— | 0—— | 0—0.0% | 0—0.0% | 0−100%0.0% | 0.2—0.6% | 0—0.0% | −0.3−128%−1.1% | 1.1+581%4.4% | 0.2r0.2—2.8% | |
| Net income attributable to shareholders | −42—— | −17−193%— | 19r−25—43.7% | −33—−128% | −46—−146% | −37—−127% | −25—−55.0% | −27—−91.9% | −18—−69.8% | −23r−23—−391% | |
| Earnings per share, basic | -3.71—— | -7.83−458%— | 2.19r-0.27—— | -0.45—— | -0.71—— | -0.68—— | -0.56—— | -0.50—— | -0.40—— | -0.55—— | |
| Earnings per share, diluted | -3.71—— | -7.83−461%— | 2.17—— | — | -0.71—— | -0.68—— | -0.56—— | -0.50—— | -0.40—— | -0.55—— | |
| Shares, weighted average (basic) | 11+405%— | 2.2+25.7%— | 1.8r90−97.6%— | 74+14.9%— | 65+18.5%— | 54—— | — | — | — | — | |
| Shares, weighted average (diluted) | 11+405%— | 2.2+24.1%— | 1.8—— | — | 65+18.5%— | 54+7.6%— | 51−4.6%— | 53+20.8%— | 44+5.3%— | 42r42—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 58−30.6%97.4% | 84+1037%94.8% | 7.4r17−81.0%97.4% | 39−67.2%40.5% | 118+67.2%76.7% | 70+13.1%67.1% | 62−16.8%44.1% | 75+97.7%53.0% | 38+29.0%36.5% | 29r29—83.7% | |
| Short-term investments | 0—0.0% | — | 9.0−56.3%119% | 21—21.5% | 0—0.0% | 0−100%0.0% | 42−21.3%29.7% | 53+53.2%37.7% | 35—33.5% | 0—0.0% | |
| Receivables | 0−100%0.0% | 0.4—0.4% | 0r0.6−100%0.0% | 5.8+75.4%6.1% | 3.3+94.2%2.2% | 1.7−74.9%1.6% | 6.8+151%4.8% | 2.7−82.6%1.9% | 16+27174%15.0% | 0.1r0.1—0.2% | |
| Other current assets | 1.0−56.2%1.7% | 2.3+1060%2.6% | 0.2r4.1−93.8%2.6% | 3.2r8.4−50.9%3.4% | 6.5+83.0%4.3% | 3.6−12.1%3.4% | 4.1−11.0%2.9% | 4.6+183%3.2% | 1.6−50.5%1.6% | 3.3r3.3—9.3% | |
| Current assets | 59−33.1%99.0% | 88+1069%100% | 7.5r39−89.7%100% | 73−42.5%76.9% | 128+68.5%83.1% | 76−34.2%72.1% | 115−15.0%81.5% | 135+50.8%95.8% | 90+175%86.4% | 33r33—93.2% | |
| Property, plant and equipment | — | — | 0−100%0.0% | 17−11.1%17.8% | 19−13.3%12.5% | 22+13.0%21.0% | 20+286%13.8% | 5.0+25.2%3.6% | 4.0+78.2%3.9% | 2.3r2.3—6.5% | |
| Right-of-use (leased) assets | 0.6—1.0% | 0—0.0% | — | 3.7−5.2%3.9% | 3.9−0.6%2.5% | 3.9+14.5%3.7% | 3.4—2.4% | 0—0.0% | — | — | |
| Long-term investments | — | — | — | — | — | — | — | 0−100%0.0% | 9.9—9.6% | 0—0.0% | |
| Total assets | 60−32.5%100% | 88+1069%100% | 7.5r39−92.1%100% | 95−37.8%100% | 154+46.2%100% | 105−25.6%100% | 141−0.2%100% | 141+36.1%100% | 104+196%100% | 35r35—100% | |
| Accounts payable | 4.6+0.2%7.7% | 4.6+390%5.2% | 0.9r3.4−77.5%12.4% | 4.2−51.7%4.4% | 8.6+382%5.6% | 1.8−69.2%1.7% | 5.8+73.2%4.1% | 3.4+36.6%2.4% | 2.5+2.8%2.4% | 2.4r2.4—6.8% | |
| Current liabilities | 11−5.8%19.0% | 12+410%13.6% | 2.4r12−93.5%31.3% | 37−27.6%38.3% | 51+128%32.9% | 22−18.0%21.1% | 27−43.8%19.1% | 48+5.0%34.0% | 46+446%44.1% | 8.4r8.4—23.9% | |
| Lease liabilities (non-current) | 0.4—0.7% | 0—0.0% | 0−100%0.0% | 12−11.5%12.8% | 14−13.1%9.0% | 16+2.9%15.2% | 15—11.0% | 0—0.0% | — | — | |
| Total liabilities | 32+23.2%53.0% | 26+124%29.0% | 11r12−83.1%151% | 68−34.3%70.8% | 103+39.0%66.9% | 74−17.6%70.5% | 90−11.5%63.6% | 101+9.8%71.7% | 92+839%88.9% | 9.8r9.8—28.1% | |
| Retained earnings | −135—−227% | −94—−106% | −76r−315—−1011% | −290—−304% | −257—−167% | −211—−201% | −174—−123% | −147—−104% | −120—−116% | −103r−103—−293% | |
| Shareholders' equity | 28−55.3%47.0% | 63—71.0% | −74r27—−987% | −94r28−285%−98.2% | 51+63.6%33.1% | 31−39.6%29.5% | 51+28.6%36.4% | 40+247%28.3% | 12−54.3%11.1% | 25r25—71.9% | |
| Total liabilities and equity | 60−32.5%100% | 88+1069%100% | 7.5r39−92.1%100% | 95−37.8%100% | 154+46.2%100% | 105−25.6%100% | 141−0.2%100% | 141+36.1%100% | 104+196%100% | 35r35—100% | |
| Shares outstanding | 12+12.4%— | 11+522%— | 1.8r99−97.6%— | 75+3.2%— | 72+29.0%— | 56+1.4%— | 55+2.0%— | 54+20.3%— | 45+4.5%— | 43—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | — | — | 1.9−31.3%4.4% | 2.8+12.6%10.7% | 2.5—7.8% | — | — | — | — | — | |
| Share-based compensation | 6.4+671%— | 0.8+37.6%— | 0.6r3.3−86.3%1.4% | 4.4−15.6%17.0% | 5.2+2.5%16.6% | 5.1−5.3%17.4% | 5.4+8.7%11.6% | 4.9+62.3%17.0% | 3.0+59.9%12.1% | 1.9r1.9—32.7% | |
| Cash from operating activities | −25—— | −11—— | −14r−54—−32.0% | −60—−231% | −7.7—−24.4% | −46—−157% | −52—−113% | −1.1−102%−3.7% | 50—197% | −14r−14—−247% | |
| Capital expenditure | — | — | −0.2—−0.4% | −1.0—−4.0% | −0.9—−3.0% | −2.7—−9.3% | −2.5—−5.3% | −1.7—−5.8% | −2.0—−7.7% | −0.6r−0.6—−9.6% | |
| Cash from investing activities | — | — | 12—28.0% | −21—−82.0% | −0.9−102%−3.0% | 39+299%134% | 9.8—21.3% | −8.9—−30.5% | −46—−182% | −0.6r−0.6—−9.6% | |
| Shares issued | — | — | 20+185%46.1% | 6.9−81.9%26.7% | 38+297%122% | 9.6—32.8% | — | — | — | — | |
| Cash from financing activities | −0.7−101%— | 87+1642%— | 5.0r20−30.7%11.7% | 7.2−87.8%27.9% | 59+485%188% | 10−68.6%34.5% | 32−33.7%69.5% | 49+1086%167% | 4.1−73.1%16.2% | 15r15—261% | |
| Exchange-rate effect on cash | 0.0+1433%— | 0.0—— | — | — | −3.2−167%−10.2% | 4.7—16.2% | −2.1—−4.6% | −1.6—−5.4% | — | — | |
| Change in cash | −26−134%— | 76—— | −8.7r−21—−20.3% | −79−267%−305% | 47+479%151% | 8.2—27.9% | −13−134%−27.2% | 37+334%127% | 8.5+141933%33.7% | 0.0r0.0—0.1% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | — | — | — | — | — | — | — | — | — | 0—— | 0—— | 0.1—100% | 1.3*—100% | |
| Research and development | 40+118%— | 11+65.8%— | 12+144%— | 9.3+129%— | 7.1*+180%— | 6.5+105%— | 5.1+255%— | 4.1+314%— | 2.5*—— | 3.2—— | 1.4r0.8—— | 1.0r1.2—1857% | — | |
| General and administrative | 31+128%— | 12+226%— | 8.9+116%— | 5.5+45.4%— | 4.2*+129%— | 3.6+94.1%— | 4.1+182%— | 3.8+390%— | 1.8*—— | 1.9r3.6—— | 1.5r3.4—— | 0.8r4.1—1462% | — | |
| Operating expenses | 70+122%— | 23+123%— | 21+131%— | 15+88.7%— | 11*+159%— | 10+101%— | 9.3+218%— | 7.9+347%— | 4.4r1.4*—— | 5.1r3.1—— | 2.9r4.2—— | 1.8r5.4—3319% | — | |
| Operating income | −70—— | −23—— | −21—— | −15—— | −11*—— | −10—— | −9.3—— | −7.9—— | −4.4r−1.5*−133%— | −5.1r−3.1—— | −2.9r−4.2—— | −1.8r−5.3—−3319% | 13r−4.5*—1030% | |
| Interest expense and finance costs | — | — | — | — | 0*−100%— | 0−100%— | 0−100%— | — | 0.2*—— | 0.2—— | 0.0—— | — | — | |
| Net interest income | 6.1+160%— | 2.6+306%— | 2.0+185%— | 1.1+42.7%— | 0.5*+85.1%— | 0.6+236%— | 0.7—— | 0.8+774%— | 0.3*—— | 0.2—— | −0.1—— | 0.1—162% | — | |
| Other non-operating income (expense) | −0.1−117%— | −0.0−118%— | −0.0−101%— | −0.0−114%— | −0.1*—— | 0.0—— | 0.6+777%— | 0.2—— | −0.0r−0.1*−100%— | −0.0r0.1—— | 0.1r0.4—— | 0r0.2—0.0% | 0.4r−0.5*—32.6% | |
| Income before tax | −75—— | −25—— | −22—— | −16—— | −13*—— | −11—— | −9.5—— | −8.2—— | −4.0*—— | −6.8—— | −4.2—— | −2.5—−4785% | — | |
| Income tax | 0—— | 0—— | 0—— | 0—— | 0*—— | 0—— | 0—— | 0—— | 0*—— | 0—— | 0—— | 0—0.0% | — | |
| Net income including minority interests | — | −25*—— | −22*—— | −16—— | — | −11*—— | −9.5*—— | −8.2—— | — | −6.8*—— | — | — | — | |
| Net income attributable to shareholders | −75—— | −25—— | −22—— | −16—— | −13*—— | −11—— | −9.5—— | −8.2—— | −4.0r−6.1*−110%— | −6.8r−2.9—— | −4.2r−3.6—— | −2.5r−4.9—−4785% | 39r−4.6*—2975% | |
| Earnings per share, basic | — | -1.70—— | -1.52—— | -1.20—— | — | -1.03—— | -0.86—— | -0.74—— | — | -3.94r-2.19—— | -2.47r-2.76—— | -1.54r-3.95—— | — | |
| Earnings per share, diluted | — | -1.70—— | -1.52—— | -1.20—— | — | -1.03—— | -0.86—— | -0.74—— | — | -3.94r-2.19—— | -2.47r-2.76—— | -1.54—— | — | |
| Shares, weighted average (basic) | 15+31.3%— | 15+31.3%— | 14+29.9%— | 13+18.8%— | — | 11+525%— | 11+524%— | 11+522%— | — | 1.8r1.3—— | 1.8r1.3—— | 1.8r1.2—— | — | |
| Shares, weighted average (diluted) | 15+31.3%— | 15+31.3%— | 14+29.9%— | 13+18.8%— | — | 11+525%— | 11+524%— | 11+522%— | — | 1.8r1.3—— | 1.8r1.3—— | 1.8—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 193—80.7% | 193+204%80.7% | 188+167%74.1% | 206+173%78.3% | 58−30.6%97.4% | 64+228%95.0% | 70+257%95.5% | 76+296%95.2% | 84+1037%94.8% | 19—94.4% | 20—78.8% | 19—64.7% | 7.4r17—97.4% | |
| Short-term investments | 43—18.1% | 43—18.1% | 63—24.8% | 55—21.0% | 0—0.0% | — | — | — | — | 0—0.0% | 0—0.0% | 0—0.0% | 9.0—119% | |
| Receivables | — | — | — | — | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 0.4—0.4% | 0.4—1.8% | 1.5—5.9% | 1.8—6.2% | 0r0.6—0.0% | |
| Other current assets | 2.3—1.0% | 2.3+98.2%1.0% | 2.4+82.9%1.0% | 1.4−24.9%0.5% | 1.0−56.2%1.7% | 1.2+312%1.7% | 1.3+106%1.8% | 1.8−38.3%2.3% | 2.3+1060%2.6% | 0.3—1.4% | 0.6—2.6% | 3.0—10.1% | 0.2r4.1—2.6% | |
| Current assets | 239—99.8% | 239+257%99.8% | 253+243%99.8% | 263+231%99.8% | 59−33.1%99.0% | 67—100% | 74—100% | 79—100% | 88+1069%100% | — | — | — | 7.5r39—100% | |
| Property, plant and equipment | — | — | — | — | — | — | — | — | — | — | — | — | 0—0.0% | |
| Right-of-use (leased) assets | 0.4—0.2% | 0.4—0.2% | 0.5—0.2% | 0.5—0.2% | 0.6—1.0% | — | — | — | 0—0.0% | — | — | — | — | |
| Total assets | 239—100% | 239+258%100% | 254+244%100% | 264+232%100% | 60−32.5%100% | 67+226%100% | 74+194%100% | 79+169%100% | 88+1069%100% | 21—100% | 25—100% | 29—100% | 7.5r39—100% | |
| Accounts payable | 5.2—2.2% | 5.2+48.3%2.2% | 6.8+48.9%2.7% | 5.4+22.6%2.1% | 4.6+0.2%7.7% | 3.5+335%5.2% | 4.6+370%6.2% | 4.4+193%5.6% | 4.6+390%5.2% | 0.8—3.9% | 1.0—3.9% | 1.5—5.1% | 0.9r3.4—12.4% | |
| Current liabilities | 15—6.2% | 15+44.8%6.2% | 12+24.2%4.7% | 9.1+1.5%3.5% | 11−5.8%19.0% | 10+142%15.4% | 9.6+51.5%13.0% | 9.0+19.2%11.3% | 12+410%13.6% | 4.3—20.7% | 6.3—25.3% | 7.5—25.5% | 2.4r12—31.3% | |
| Lease liabilities (non-current) | 0.3—0.1% | 0.3—0.1% | 0.3—0.1% | 0.4—0.1% | 0.4—0.7% | — | — | — | 0—0.0% | — | — | — | 0—0.0% | |
| Total liabilities | 41—17.3% | 41+46.8%17.3% | 37+41.1%14.5% | 31+31.8%11.9% | 32+23.2%53.0% | 28—42.2% | 26—35.2% | 24—30.0% | 26+124%29.0% | — | — | — | 11r12—151% | |
| Retained earnings | −198—−82.6% | −198—−82.6% | −173—−68.3% | −151—−57.3% | −135—−227% | −123—−183% | −111—−151% | −102—−128% | −94—−106% | −326—−1590% | −323—−1291% | −320—−1084% | −76r−315—−1011% | |
| Shareholders' equity | 198—82.7% | 198+412%82.7% | 217+354%85.5% | 232+318%88.1% | 28−55.3%47.0% | 39—57.8% | 48—64.8% | 56—70.0% | 63—71.0% | −87r16—−426% | −81r19—−323% | −77r22—−261% | −74r27—−987% | |
| Total liabilities and equity | 239—100% | 239+258%100% | 254+244%100% | 264+232%100% | 60−32.5%100% | 67+226%100% | 74+194%100% | 79+169%100% | 88+1069%100% | 21—100% | 25—100% | 29—100% | 7.5r39—100% | |
| Shares outstanding | 15—— | 15+31.7%— | 14+30.2%— | 14+29.9%— | 12+12.4%— | 11+740%— | 11+738%— | 11+791%— | 11+522%— | 1.3—— | 1.3—— | 1.2—— | 1.8r99—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | — | — | — | 0*—— | 0*—— | −0.0—−56.6% | — | |
| Share-based compensation | 16+250%— | 5.4+203%— | 5.2+260%— | 3.4+209%— | 2.1*+678%— | 1.8+799%— | 1.4+560%— | 1.1+649%— | 0.3*—— | 0.2—— | 0.2—— | 0.1r0.5—275% | — | |
| Cash from operating activities | −43—— | −14*—— | −13*—— | −11—— | −4.9*—— | −7.9*—— | −5.4*—— | −6.8—— | −5.4r−2.5*−126%— | −2.7r0.1*—— | −1.6r−1.5*—— | −1.1r−7.0—−2079% | 20r−20*—1574% | |
| Capital expenditure | — | — | — | — | — | — | — | — | — | 0*—— | 0*—— | 0—0.0% | — | |
| Cash from investing activities | — | 20*—— | −7.0*—— | −55—— | — | 0*−100%— | 0*−100%— | 0−100%— | — | 0.1*—— | 2.2*—— | 9.0—16981% | 3.4*—266% | |
| Shares issued | — | 0*—— | 0*—— | 230—— | — | 0*—— | 0*—— | 0—— | — | 0*—— | — | — | 0*—0.0% | |
| Cash from financing activities | 216+192%— | 0.5*+86.8%— | 1.3*+267%— | 215—— | −0.0*−100%— | 0.2*−90.0%— | 0.3*−96.5%— | −1.2—— | 75r87*—— | 2.4r0*—— | 9.9r0*—— | 0—0.0% | −15r0.0*—−1138% | |
| Exchange-rate effect on cash | −0.7−209%— | −0.1*−113%— | 0.0*—— | −0.0—— | −0.6*−20433%— | 0.8*—— | −0.1*—— | −0.0—— | 0.0*—— | 0*—— | 0*—— | 0—0.0% | — | |
| Change in cash | 130+163%— | 5.5*—— | −19*—— | 148—— | −5.6*−108%— | −6.9*—— | −5.2*−163%— | −8.0—— | 69r74*—— | −0.3r−0.4*—— | 8.3r0.6*—— | −1.1r1.7—−2079% | −3.0r−15*—−228% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Where Palvella Therapeutics, Inc. operates: 2 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 2 subsidiaries on file.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters1 office1 subsidiary | — |
| 🇩🇪 Germany | 1 subsidiary | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file; map outlines from Natural Earth. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Executive pay at Palvella Therapeutics, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Wesley H. Kaupinen | $3.4 M | $57.1 M | $2.0 M | $126 |
| 2024Wesley H. Kaupinen | $5.1 M | $4.6 M | $1.2 M | $14 |
| 2023Wesley H. Kaupinen | $1.4 M | $554 K | $717 K | $18 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Palvella Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 3 · Material agreement 1 · Shareholder vote 2 · Results announced 9
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 5, 2026
Acquisitions and funding#
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2019 | $32 M | Private placement after listing | $10 to $50 million | 9 | equity, options | SEC |
| Jun 2016 | $17 M | Private placement after listing | $10 to $50 million | 15 | equity, options | SEC |
| Dec 2014 | $40 M | Issued in a merger or acquisition | $10 to $50 million | 21 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at Palvella Therapeutics, Inc.#
2 labor condition applications certified in fiscal 2025 for 2 positions, at a median wage of $128 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Analytical Development ScientistChemists | 2 | $128 K |
Where: Wayne, PA 2
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Palvella Therapeutics, Inc.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 70% of workforce | Restructuring planSEC 8-K | “In connection therewith, on July 17, 2023, the Board of Directors of the Company approved a reduction in force of the Company's workforce by approximately 70% to be substantially c…” | Filing | |
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing |
Source: State WARN notices and SEC 8-K item 2.05
Discuss Palvella Therapeutics, Inc.#
3 automatic updates and 0 member comments. Sign in to comment and react.
- Results announced on 5 November 2026automatic update · Nov 5, 2026
Palvella Therapeutics, Inc. announced results on 5 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: a net loss of $25 million.
- Insider trading in October 2026automatic update · Oct 31, 2026
Directors and officers of Palvella Therapeutics, Inc. reported open-market trades for October 2026 (SEC Forms 4 and 5): 2 insiders sold shares worth about $4,116,784 in 20 trades. Awards, option exercises and shares withheld for tax are not counted.
- Mutual funds: 163 funds hold $694 millionautomatic update · Jul 31, 2026
163 mutual funds in 1 country hold shares of Palvella Therapeutics, Inc. worth $694 million, about 32.9% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 107 funds added shares and 29 sold; on balance they bought $131 million. Share splits are not counted as trading.
How Palvella Therapeutics, Inc. compares in Biotechnology
- Market cap$2.2 B · higher than 81% of 726
- Revenue$29 M · higher than 53% of 647
- Net margin-127.0% · higher than 39% of 408
- Revenue growth65.3% · higher than 78% of 438
- Price / sales73.6× · lower than 14% of 339
- Price / book77.0× · lower than 2% of 534
- FCF yield-0.6% · higher than 85% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Palvella Therapeutics, Inc.🇺🇸 | $2.2 B | — | -127.0% | +65.3% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Oct 29, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of March 25, 2026
- Profile updated:
- Nov 20, 2026
Figures from Market data, value.today research, GLEIF register, SEC filing.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Palvella Therapeutics, Inc.? Verify and update this profile — free
Show Palvella Therapeutics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.